Immunodermatology News

Priority review of a supplemental new drug application for ruxolitinib for the treatment of vitiligo has been accepted by the FDA, Incyte announced in a press release.

Patients with alopecia areata who were treated with ritlecitinib or brepocitinib had significant downregulation of immune biomarkers, according to a biopsy sub-study.

More than one-third of individuals with hidradenitis suppurativa reported using alternative medicine approaches, regardless of age or disease severity, according to a study.

Combining alexandrite laser treatment and oral zinc could help decrease hidradenitis suppurativa severity, according to a study.

Patients with rheumatoid arthritis, gout, polydermatomyositis, vasculitis and those with multiple rheumatic diseases were at greatest risk for breakthrough COVID-19 infection, despite full or partial vaccination vs. those without rheumatic disease.

Managing oral, ocular and cutaneous complications is critical to optimizing outcomes in conditions ranging from Sjögren’s syndrome to juvenile dermatomyositis, according to a presenter who offered a cross-section of “pearls and myths” at ACR Convergence 2021.

Black patients with systemic sclerosis had multiple poor prognostic features compared with non-Black patients, putting them at higher risk for mortality, according to data presented at ACR Convergence 2021.

A prediction model presented at ACR Convergence 2021 demonstrated that the use of platelet inhibitors could predict a lower probability of digital ulcer occurrence among patients with systemic sclerosis.

Using the most recent EULAR/American College of Rheumatology criteria, researchers at the Mayo Clinic and the Karolinska Institute determined that the incidence and prevalence of dermatomyositis are higher than previously reported.

An immune response may be responsible for “COVID toes,” chilblain-like lesions associated with COVID-19 infection, according to a study published in the British Journal of Dermatology.